NORMOCARB HF 25
LOE Approachingmagnesium chloride; sodium bicarbonate; sodium chloride
NDAINJECTIONSOLUTION
Approved
Jul 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORMOCARB HF 25 is an injectable solution containing magnesium chloride, sodium bicarbonate, and sodium chloride used for electrolyte and acid-base balance management in clinical settings. This combination product functions as a buffer and electrolyte replacement therapy for patients requiring parenteral support. The product addresses critical care needs in hospital and acute care environments.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30 rating); expect declining team investment and potential consolidation of support roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and LOE approaching, this product represents a declining career opportunity within the organization. Roles are likely defensive and focused on cost management, compliance, and operational efficiency rather than growth or innovation.
Regulatory Affairs SpecialistSupply Chain Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.